Category Archives: Lung Cancer

Publication: Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

Thomas R. Cox, Jan 2021

Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours

Congratulations to Kaitlin and Yordanos who just had their co-first author review published in Cancers as part of a special edition on Treating the Cancer Matrix: Progress in the Identification of Potential Therapeutic Targets. Also a shout out to Rhiannon for her amazing illustrator skills and creating some beautiful figures. And finally to Jess, who as co-senior author played an instrumental role in bringing everything together.

Extracellular matrix in cancer
Remodeling of the extracellular matrix (ECM) in solid tumours. In healthy tissue, the ECM has a structured basement membrane consisting primarily of collagens IV and VI as well as a scaffolding arrangement of fibrillar collagens that are predominantly secreted by the fibroblasts. In comparison, solid tumours typically consist of more densely packed, aberrantly cross-linked fibrillar collagens resulting from the recruitment and activation of CAFs. As the level of deposition of fibrillar collagens such as collagens I, III and V increases in the tumour ECM, so too does LOX family mediated collagen cross-linking. In addition, tumour ECM results in a breakdown of the structure of the normal basement membrane.
Continue reading

Publication: The Role of the ECM in Lung Cancer Dormancy and Outgrowth

Thomas R. Cox, Sep 2020

The Role of the ECM in Lung Cancer Dormancy and Outgrowth

We are pleased to report that our recent in depth review on the role of the extracellular matrix (ECM) in Lung cancer, both in primary and metastatic settings has just been published as part of a special edition on ‘Revisiting Seed and Soil: A New Approach to Target Hibernating Dormant Tumor Cells‘ in Frontiers in Oncology: Molecular and Cellular Oncology.

Extracellular Matrix in Lung Cancer
Continue reading

People: Amelia joins the team

Thomas R. Cox, Aug 2019

It’s with great excitement that we welcome our newest PostDoc to the team, Amelia Parker.

ameparAmelia joins us having returned from a PostDoctoral position at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in the USA. Prior to this she completed her Ph.D. in the laboratories of Professor Maria Kavallaris and A/Prof Joshua McCarroll at The Children’s Cancer Institute (CCI) in Sydney.

As a biomedical engineer and cancer biologist, Amelia is interested in the importance of the tumour microenvironment, and in particular the extracellular matrix (ECM) in driving tumour progression.

Amelia’s work will focus on the importance of the ECM in Lung Cancer onset and progression.

Publication: LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity

Thomas R. Cox, May 2019

LOXL1 Is Regulated by Integrin α11 and Promotes Non-Small Cell Lung Cancer Tumorigenicity

Our lab has contributed to a recent paper by Zeltz and colleagues looking at the interplay between Lysyl Oxidase Like 1 (LOXL1) and Integrin α11 in Non-Small Cell Lung Cancer (NSCLC). The work was published in the Open-Access journal Cancers.

LOXL1, integrin a11 and ECM crosstalk

Continue reading